BeOne Medicines (NASDAQ:ONC) COO Sells $361,993.32 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,357 shares of BeOne Medicines stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $266.76, for a total value of $361,993.32. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The stock was sold at an average price of $261.20, for a total transaction of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Price Performance

BeOne Medicines stock traded up $7.47 during mid-day trading on Thursday, hitting $270.15. 367,884 shares of the company traded hands, compared to its average volume of 260,552. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The stock has a market cap of $29.64 billion, a price-to-earnings ratio of 60.44 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The stock has a fifty day moving average price of $296.83 and a 200-day moving average price of $312.94.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. On average, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of ONC. EFG International AG bought a new position in BeOne Medicines during the 4th quarter worth approximately $25,000. Leonteq Securities AG purchased a new stake in shares of BeOne Medicines during the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. purchased a new stake in shares of BeOne Medicines during the second quarter valued at approximately $35,000. CWM LLC grew its holdings in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the last quarter. Finally, Group One Trading LLC bought a new position in shares of BeOne Medicines in the fourth quarter worth approximately $61,000. Institutional investors own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Jefferies Financial Group cut BeOne Medicines from a “buy” rating to a “hold” rating and reduced their target price for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Wells Fargo & Company initiated coverage on BeOne Medicines in a report on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective on the stock. Finally, Truist Financial restated a “buy” rating and issued a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.